Eileen's Story – Savings from Biosimilar Medicines | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.

Eileen's Story – Savings from Biosimilar Medicines

“I’ve been fighting Crohn’s disease with a biologic medication for as long as I can remember. When I turned 26, I switched health care plans, and the biologic that I had been taking for years wasn’t covered anymore, but my doctor knew of a biosimilar that would be. So we made the change, and now I don’t pay anything for my infusions. I hope that others can have the same access and that more biosimilars will become available on insurance plans in the future. I can’t imagine not having access.” — Eileen, 28, New York, NY.

Savings from biosimilars for patients like Greg totaled $8 billion in 2020 and are projected to save $133 billion over the next five years.

View Patient Stories

AAM Voices of Access 2022

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.